A) A431 cells were grown under the following conditions; normoxia (Nx), hypoxia (Hx), hypoxia+normoxia (Hx+Nx), normoxia+EGF (Nx+E), normoxia+EGF+Cetuximab (Nx+E+D) or hypoxia+Cetuximab (Hx+D). Cell lysate was prepared and analyzed by immunoblotting with anti-EGFR (extracellular or intracellular) primary antibodies or anti-GAPDH primary antibody. B) The A431 cell lysate prepared as described in panel A was analyzed by immunoblotting with anti-N-WASP primary antibodies or anti-GAPDH primary antibody.